Quick identification and testing of blood infections using whole blood samples
Official title: Rapid ID and AST Directly from Whole Blood Using Single Molecule Detection
Funded at Scanogen, INC. · NIH-11040347 · Data updated 2026-11-12
This study is working on a fast test that can quickly find infections in your blood and check which antibiotics will work best, helping doctors treat you more effectively and sooner.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scanogen, INC. NIH-funded |
| Lab location | 1 site (Baltimore, UNITED STATES) |
| Project start | January 30, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $785,440 |
| NIH project number | 5R01AI175063-03 |
| Project ID | NIH-11040347 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients experiencing bloodstream infections, particularly those at risk of antibiotic-resistant infections.
✕Less likely to help
Patients who do not have bloodstream infections or those whose infections are not caused by bacteria may not benefit from this research.
What this research studies
This research aims to develop a rapid diagnostic platform that can identify bloodstream infections and test for antibiotic susceptibility directly from whole blood samples. By utilizing a novel technique called Single MOlecule Tethering (SMOLT), the platform is designed to provide results within hours instead of days, allowing for timely and targeted treatment. The approach focuses on detecting bacteria and determining their resistance to antibiotics quickly, which is crucial for effective patient care. If successful, this method could significantly improve the management of infections caused by resistant organisms.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective treatment options for patients with bloodstream infections.
How similar studies have gone: Other research has shown promise in rapid diagnostic techniques for infections, suggesting that this approach could be a significant advancement in the field.
Where this research is happening
-
Scanogen, INC.
Baltimore, United States Active
Researchers
- Principal investigator: Celedon, Alfredo Andres — Scanogen, INC.
- Study coordinator: Celedon, Alfredo Andres
Related research
Other NIH-funded projects on the same topics.
-
Bloodstream infection detection directly on whole blood
A new automated test detects yeast infections in a patient’s blood quickly, helping doctors start the right antifungal treatment sooner.
-
Bloodstream yeast infection test directly from blood
A new automated test kit can detect most yeasts causing bloodstream infections directly from a patient’s blood to help doctors start the right antifungal treatment sooner.
-
Fast blood test to find bacteria and tell which antibiotics will work
A new blood test that finds bacteria and shows which antibiotics will work for people with suspected bloodstream infections.
-
Faster diagnosis for yeast bloodstream infections
This work is creating a quick test to find yeast infections in the blood, helping doctors treat patients faster.
-
Rapid blood test to detect many bloodstream infections
A fast blood test that finds many different germs directly from whole blood for people with suspected bloodstream infections or sepsis.
-
Rapid diagnosis of bacterial sepsis without culture
This study is testing a new, fast way to find bacteria in blood samples from patients with sepsis, so doctors can start the right treatment in just one hour instead of waiting days, making it easier for everyone involved.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.